These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

349 related articles for article (PubMed ID: 26467815)

  • 1. Targeting bone marrow lymphoid niches in acute lymphoblastic leukemia.
    Uy GL; Hsu YM; Schmidt AP; Stock W; Fletcher TR; Trinkaus KM; Westervelt P; DiPersio JF; Link DC
    Leuk Res; 2015 Dec; 39(12):1437-42. PubMed ID: 26467815
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Patient-Derived Bone Marrow Spheroids Reveal Leukemia-Initiating Cells Supported by Mesenchymal Hypoxic Niches in Pediatric B-ALL.
    Balandrán JC; Dávila-Velderrain J; Sandoval-Cabrera A; Zamora-Herrera G; Terán-Cerqueda V; García-Stivalet LA; Limón-Flores JA; Armenta-Castro E; Rodríguez-Martínez A; Leon-Chavez BA; Vallejo-Ruiz V; Hassane DC; Pérez-Tapia SM; Ortiz-Navarrete V; Guzman ML; Pelayo R
    Front Immunol; 2021; 12():746492. PubMed ID: 34737747
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Bone marrow stromal cells and the upregulation of interleukin-8 production in human T-cell acute lymphoblastic leukemia through the CXCL12/CXCR4 axis and the NF-kappaB and JNK/AP-1 pathways.
    Scupoli MT; Donadelli M; Cioffi F; Rossi M; Perbellini O; Malpeli G; Corbioli S; Vinante F; Krampera M; Palmieri M; Scarpa A; Ariola C; Foà R; Pizzolo G
    Haematologica; 2008 Apr; 93(4):524-32. PubMed ID: 18322253
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ifosfamide with mesna uroprotection and etoposide in recurrent, refractory acute leukemia in childhood. A Pediatric Oncology Group Study.
    Bernstein ML; Whitehead VM; Devine S; Grier H; Kung F; Krischer J; Dreyer Z; Bell B; Land V; Buchanan GR
    Cancer; 1993 Sep; 72(5):1790-4. PubMed ID: 8348510
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Residual bone marrow leukemic progenitor cell burden after induction chemotherapy in pediatric patients with acute lymphoblastic leukemia.
    Uckun FM; Stork L; Seibel N; Sarquis M; Bedros C; Sather H; Sensel M; Reaman GH; Gaynon PS
    Clin Cancer Res; 2000 Aug; 6(8):3123-30. PubMed ID: 10955793
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting the bone marrow microenvironment in acute leukemia.
    Karantanou C; Godavarthy PS; Krause DS
    Leuk Lymphoma; 2018 Nov; 59(11):2535-2545. PubMed ID: 29431560
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Disturbed CXCR4/CXCL12 axis in paediatric precursor B-cell acute lymphoblastic leukaemia.
    van den Berk LC; van der Veer A; Willemse ME; Theeuwes MJ; Luijendijk MW; Tong WH; van der Sluis IM; Pieters R; den Boer ML
    Br J Haematol; 2014 Jul; 166(2):240-9. PubMed ID: 24697337
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Factors determining pbsc mobilization efficiency and nonmobilization following ICE with or without rituximab (R-ICE) salvage therapy for refractory or relapsed lymphoma prior to autologous transplantation.
    Xia W; Ma CK; Reid C; Bai L; Wong K; Kerridge I; Ward C; Greenwood M
    J Clin Apher; 2014 Dec; 29(6):322-30. PubMed ID: 24944079
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upregulated microRNA-146a expression induced by granulocyte colony-stimulating factor enhanced low-dosage chemotherapy response in aged acute myeloid leukemia patients.
    Li X; Xu L; Sheng X; Cai J; Liu J; Yin T; Xiao F; Chen F; Zhong H
    Exp Hematol; 2018 Dec; 68():66-79.e3. PubMed ID: 30208330
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toxicity and efficacy of intensive chemotherapy for children with acute lymphoblastic leukemia (ALL) after first bone marrow or extramedullary relapse.
    Thomson B; Park JR; Felgenhauer J; Meshinchi S; Holcenberg J; Geyer JR; Avramis V; Douglas JG; Loken MR; Hawkins DS
    Pediatr Blood Cancer; 2004 Oct; 43(5):571-9. PubMed ID: 15382275
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A study of rituximab and ifosfamide, carboplatin, and etoposide chemotherapy in children with recurrent/refractory B-cell (CD20+) non-Hodgkin lymphoma and mature B-cell acute lymphoblastic leukemia: a report from the Children's Oncology Group.
    Griffin TC; Weitzman S; Weinstein H; Chang M; Cairo M; Hutchison R; Shiramizu B; Wiley J; Woods D; Barnich M; Gross TG;
    Pediatr Blood Cancer; 2009 Feb; 52(2):177-81. PubMed ID: 18816698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment of relapsed acute lymphoblastic leukemia after allogeneic bone marrow transplantation with chemotherapy followed by G-CSF-primed donor leukocyte infusion: a prospective study.
    Choi SJ; Lee JH; Lee JH; Kim S; Lee YS; Seol M; Ryu SG; Lee JS; Kim WK; Jang S; Park CJ; Chi HS; Lee KH
    Bone Marrow Transplant; 2005 Jul; 36(2):163-9. PubMed ID: 15937507
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Advances in understanding the acute lymphoblastic leukemia bone marrow microenvironment: From biology to therapeutic targeting.
    Chiarini F; Lonetti A; Evangelisti C; Buontempo F; Orsini E; Evangelisti C; Cappellini A; Neri LM; McCubrey JA; Martelli AM
    Biochim Biophys Acta; 2016 Mar; 1863(3):449-463. PubMed ID: 26334291
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Concept and interim result of the ALL-BFM 90 therapy study in treatment of acute lymphoblastic leukemia in children and adolescents: the significance of initial therapy response in blood and bone marrow].
    Schrappe M; Reiter A; Sauter S; Ludwig WD; Wörmann B; Harbott J; Bender-Götze C; Dörffel W; Dopfer R; Frey E
    Klin Padiatr; 1994; 206(4):208-21. PubMed ID: 7526027
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential chemosensitivity of leukemic cells in the myeloid and lymphoid phases of stem cell leukemia (a case report).
    Mihál V; Hajdúch M; Dusek J; Jarosová M; Weigl E; Pikalová Z; Indrák K; Safárová M; Janostáková A
    Neoplasma; 1997; 44(2):133-6. PubMed ID: 9201294
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Autologous transplantation of chemotherapy-purged PBSC collections from high-risk leukemia patients: a pilot study.
    Lemoli RM; Visani G; Leopardi G; Motta MR; Rizzi S; Testoni N; Curti A; Tura S
    Bone Marrow Transplant; 1999 Feb; 23(3):235-41. PubMed ID: 10084254
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Ifosfamide, etoposide, cytarabine, and methotrexate as salvage chemotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Stamatoullas A; Fruchart C; Bastit D; Boulet D; Moncondult M; Piguet H; Tilly H
    Cancer; 1996 Jun; 77(11):2302-7. PubMed ID: 8635099
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low-dose cytarabine and aclarubicin combined with granulocyte colony-stimulating factor for the treatment of relapsed or primary refractory acute lymphocytic leukemia: a retrospective study of 25 Chinese patients.
    Xue SL; Cui HX; Zou JY; Xue MX; Tang XW; Zhang YM; Wu DP
    Hematol Oncol; 2013 Dec; 31(4):206-12. PubMed ID: 23616245
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of low-dose cytarabine and aclarubicin in combination with granulocyte colony-stimulating factor (CAG regimen) compared to Hyper-CVAD regimen as salvage chemotherapy in relapsed/refractory Philadelphia chromosome-negative acute lymphoblastic leukemia.
    Liu L; Jiao W; Zhang Y; Qu Q; Li X; Wu D
    Leuk Res; 2015 Mar; 39(3):323-8. PubMed ID: 25638269
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Regulation of the bone marrow microenvironment by G-CSF: Effects of G-CSF on acute lymphoblastic leukaemia.
    Basnett J; Xie V; Cisterne A; Bradstock K; Bendall L
    PLoS One; 2017; 12(11):e0188042. PubMed ID: 29145456
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.